ChemoCentryx, Inc.
(NASDAQ : CCXI)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -0.58%160.970.7%$1260.98m
LLYEli Lilly & Co. -0.50%331.281.1%$1100.53m
ABBVAbbVie, Inc. -0.80%139.171.9%$853.68m
PFEPfizer Inc. -1.46%42.460.9%$791.52m
BMYBristol-Myers Squibb Co. -0.13%70.151.0%$750.83m
MRKMerck & Co., Inc. 0.55%87.920.7%$701.48m
AZNAstraZeneca Plc 1.98%56.001.0%$393.86m
ALNYAlnylam Pharmaceuticals, Inc. -0.52%201.318.2%$223.65m
GSKGSK Plc 1.27%30.380.3%$211.16m
NVSNovartis AG -0.03%76.020.2%$200.85m
HZNPHorizon Therapeutics Plc -2.92%65.915.4%$183.20m
IDXXIDEXX Laboratories, Inc. -2.93%335.883.9%$178.93m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.495.4%$178.81m
SRPTSarepta Therapeutics, Inc. -0.57%114.1712.4%$140.93m
NVONovo Nordisk A/S -0.93%104.840.1%$131.88m

Company Profile

ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA.